These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 36332588)

  • 21. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 22. Developing an opioid use disorder treatment cascade: A review of quality measures.
    Williams AR; Nunes EV; Bisaga A; Pincus HA; Johnson KA; Campbell AN; Remien RH; Crystal S; Friedmann PD; Levin FR; Olfson M
    J Subst Abuse Treat; 2018 Aug; 91():57-68. PubMed ID: 29910015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. College students' perceived knowledge of and perceived helpfulness of treatments for opioid use disorder at two American universities.
    Andraka-Christou B; Nguyen T; Harris S; Madeira J; Totaram R; Randall-Kosich O; Atkins D; Ford J
    Am J Drug Alcohol Abuse; 2020 Sep; 46(5):589-603. PubMed ID: 32543922
    [No Abstract]   [Full Text] [Related]  

  • 24. The impact of cannabis on non-medical opioid use among individuals receiving pharmacotherapies for opioid use disorder: a systematic review and meta-analysis of longitudinal studies.
    Costa GPA; Nunes JC; Heringer DL; Anand A; De Aquino JP
    Am J Drug Alcohol Abuse; 2024 Jan; 50(1):12-26. PubMed ID: 38225727
    [No Abstract]   [Full Text] [Related]  

  • 25. Access to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults: A Systematic Review.
    Pilarinos A; Bromberg DJ; Karamouzian M
    JAMA Pediatr; 2022 Mar; 176(3):304-311. PubMed ID: 34870707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of methadone, buprenorphine, and naltrexone on actigraphy-based sleep-like parameters in male rhesus monkeys.
    Berro LF; Zamarripa CA; Talley JT; Freeman KB; Rowlett JK
    Addict Behav; 2022 Dec; 135():107433. PubMed ID: 35901553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The SOMATICS collaborative: Introduction to a National Institute on Drug Abuse cooperative study of pharmacotherapy for opioid treatment in criminal justice settings.
    Chandler RK; Finger MS; Farabee D; Schwartz RP; Condon T; Dunlap LJ; Zarkin GA; McCollister K; McDonald RD; Laska E; Bennett D; Kelly SM; Hillhouse M; Mitchell SG; O'Grady KE; Lee JD
    Contemp Clin Trials; 2016 May; 48():166-72. PubMed ID: 27180088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perceived social support in patients with chronic pain with and without opioid use disorder and role of medication for opioid use disorder.
    Benville JR; Compton P; Giordano NA; Cheatle MD
    Drug Alcohol Depend; 2021 Apr; 221():108619. PubMed ID: 33667781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world effectiveness of pharmacological treatments of opioid use disorder in a national cohort.
    Heikkinen M; Taipale H; Tanskanen A; Mittendorfer-Rutz E; Lähteenvuo M; Tiihonen J
    Addiction; 2022 Jun; 117(6):1683-1691. PubMed ID: 35072314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Barriers to initiate buprenorphine and methadone for opioid use disorder treatment with postdischarge treatment linkage.
    Calcaterra SL; Lockhart S; Natvig C; Mikulich S
    J Hosp Med; 2023 Oct; 18(10):896-907. PubMed ID: 37608527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders.
    Mintz CM; Presnall NJ; Xu KY; Hartz SM; Sahrmann JM; Bierut LJ; Grucza RA
    Drug Alcohol Depend; 2021 Sep; 226():108886. PubMed ID: 34245997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting.
    Carswell N; Angermaier G; Castaneda C; Delgado F
    Hosp Pract (1995); 2022 Oct; 50(4):251-258. PubMed ID: 35837678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnosis and Management of Opioid Use Disorder in Hospitalized Patients.
    Herscher M; Fine M; Navalurkar R; Hirt L; Wang L
    Med Clin North Am; 2020 Jul; 104(4):695-708. PubMed ID: 32505261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women.
    Tran TH; Griffin BL; Stone RH; Vest KM; Todd TJ
    Pharmacotherapy; 2017 Jul; 37(7):824-839. PubMed ID: 28543191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Opioid use disorder treatment for people experiencing homelessness: A scoping review.
    McLaughlin MF; Li R; Carrero ND; Bain PA; Chatterjee A
    Drug Alcohol Depend; 2021 Jul; 224():108717. PubMed ID: 33985863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics and current clinical practices of opioid treatment programs in the United States.
    Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
    Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding and co-managing medication treatment options for opioid use disorder.
    Kay A; Shmuts R; Beck M
    Intern Emerg Med; 2022 Oct; 17(7):2159-2165. PubMed ID: 35138549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
    Shulman M; Weiss R; Rotrosen J; Novo P; Costello E; Nunes EV
    Addict Sci Clin Pract; 2021 Mar; 16(1):15. PubMed ID: 33676577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acceptability and efficacy of naltrexone for criminal justice-involved individuals with opioid use disorder: a systematic review and meta-analysis.
    Bahji A; Carlone D; Altomare J
    Addiction; 2020 Aug; 115(8):1413-1425. PubMed ID: 31863669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
    Biondi BE; Vander Wyk B; Schlossberg EF; Shaw A; Springer SA
    Addict Sci Clin Pract; 2022 Mar; 17(1):15. PubMed ID: 35255967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.